MilliporeSigma’s Process Solutions group offered the biopharma industry an impressive set of services and products. These offerings, along with MilliporeSigma’s deep expertise, uniquely positioned the company to help its customers navigate the complex and risky process of developing large molecule drugs. But MilliporeSigma needed to become better known for working with biopharma companies at a higher level; not just as a supplier or service provider, but as a business-model innovator.
What’s the impact of a blockbuster biologic falling off patent? Will capacity be there to make newly approved mAbs? And what’s that got to do with the price of a biosimilar in China?
In developing the Go Beyond Today’s Biopharma creative campaign, Linus and MilliporeSigma looked at questions like these as the questions that keep industry executives up at night, pondering the balance between risk and control. Then we asked ourselves a question: how could we speak to these concerns, thereby leading the Go Beyond Biopharma conversation?
First, MilliporeSigma partnered with the Economist Intelligence Unit, the research arm of The Economist newspaper, to survey 254 biopharma executives and produce a report on the results. Then, MilliporeSigma used the findings to create a series of outbound ads, a campaign site, an interactive data visualization, a blog, and social media, transforming the survey results into a rich experience and ongoing conversation on the future of biopharma.
The Go Beyond Today’s Biopharma campaign launched at the BIO 2016 International Conference, resulting in media attention and significant lead generation for MilliporeSigma. In the first month...
14 Media outlets reported on campaign
760 Report downloads
5,774 Unique pageviews
In the end, it's all about making a connection.